Preview of an industry presentation on an autologous natural killer cell therapy's clinical development and China-focused regulatory and partnership strategy.
Key Takeaways
- Company will present its cryopreserved NK cell therapy at BIOCHINA on 10 July 2026
- Troculeucel is being evaluated in a Phase 2 clinical trial for Alzheimer's disease
- NkGen will seek Chinese regulatory guidance and partnerships with pharma and CDMOs for expansion